ImmunityBio’s (IBRX) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a $8.00 price objective on the stock. HC Wainwright also issued estimates for ImmunityBio’s Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 […]
More Stories
UK Sanctions Russia After Inquiry Holds Putin Responsible for 2018 Novichock Poisonings
By Guy Birchall The UK issued new sanctions on Russia on Dec. 4, after a public inquiry into the death...
Indiana House Passes New Congressional Map Favoring Republicans
By Arjun Singh The Indiana House of Representatives on Dec. 5 passed a bill that would revise the state’s maps...
Economists Forecast Stronger US Growth, Lingering Inflation in 2026
By Tom Ozimek The U.S. economy will grow faster next year than previously projected and inflationary pressures will tick down,...
Noem Says US Travel Ban to Expand to Over 30 Countries
By Aldgra Fredly Homeland Security Secretary Kristi Noem said on Dec. 4 that the Trump administration is looking to increase...
Supreme Court Will Hear Trump’s Birthright Citizenship Case
By Matthew Vadum The U.S. Supreme Court decided on Dec. 5 to review whether President Donald Trump’s executive order ending birthright...
The Best Food Scene You Don’t Know About Is in Buffalo, New York
By Adam Reiner, Bloomberg News Buffalo might be synonymous with hot wings, but there’s a less heralded bar staple that...